Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

Published Date: 01 Mar 2023

United Kingdom: AstraZeneca has announced that it has received European Union (EU) approval for the immuno-oncology drug combination Imfinzi (active ingredient durvalumab) and Imjudo (tremelimumab).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does Maintenance Therapy Extend Life in mCRC?

2.

What does it mean for Biden's prostate cancer to be 'aggressive'? A urologic surgeon explains

3.

Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement

4.

Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.

5.

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot